Anti-metallothionein IgG and levels of metallothionein in autistic children with GI disease
A J Russo
Mount Saint Mary’s University, Emmitsburg, MD, USA
Aim: To assess both serum concentration of metallotionein (MT) and anti-metallothionein (anti-MT) immunoglobulin G (IgG) in autistic children with gastrointestinal (GI) symptoms and controls, and to test the hypothesis that there is an association between the presence of MT, anti-MT IgG, and inflammatory GI disease seen in many children with autistic spectrum disorder (ASD).
Subjects and methods: ELISAs were used to measure serum MT and anti-MT IgG in 41 autistic children with chronic digestive disease (many with ileo-colonic lymphoid nodular hyperplasia [LNH] and inflammation of the colorectum, small bowel, and/or stomach), and 33 controls (17 age-matched autistic children with no GI disease and 16 age-matched children without autism or GI disease).
Results: Ten of 41 autistic children with chronic digestive disease had high serum concentration of MT compared to only one of the 33 controls (p < 0.01). Thirteen of the 41 autistic children with chronic digestive disease had anti-MT IgG compared to only four of 33 controls (p < 0.01). Nine of 10 (90%) of autistic children with GI disease with high MT levels had a regressive onset (compared to the expected 25 of 41, or 61%, in this group) (p < 0.05), whereas only nine of 13 of the autistic children with GI disease and anti-MT IgG had a regressive onset (70%) which was not significantly higher than the expected. We didn’t find any correlation between severity of GI disease and MT concentration or anti-MT IgG.
Discussion: These results suggest a relationship between MT, anti-MT IgG and GI disease seen in many ASD individuals.
Keywords: autism, metallothionein, anti-metallothionein, GI disease
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]
Other article by this author:
Anthony J Russo, Arthur Krigsman, Bryan Jepson, et al
Published Date: 11 August 2009
Readers of this article also read:
Abdallah B, Irani J, Sailian SD, Gebran VG, Rizk U
Published Date: 13 November 2014
Patchy distributions of myelin and vesicular glutamate transporter 2 align with cytochrome oxidase blobs and interblobs in the superficial layers of the primary visual cortex
Rockoff EC, Balaram P, Kaas JH
Published Date: 24 September 2014
Moloney TP, Oâ€™Hagan S, Lee L
Published Date: 20 August 2014
Sawosz E, Jaworski S, Kutwin M, Hotowy A, Wierzbicki M, Grodzik M, Kurantowicz N, Strojny B, LipiÅ„ska L, Chwalibog A
Published Date: 14 August 2014
MR imaging and targeting of a specific alveolar macrophage subpopulation in LPS-induced COPD animal model using antibody-conjugated magnetic nanoparticles
Al Faraj A, Shaik AS, Afzal S, Al Sayed B, Halwani R
Published Date: 24 March 2014
Is higher body temperature beneficial in ischemic stroke patients with normal admission CT angiography of the cerebral arteries?
Kvistad CE, Khanevski A, Nacu A, Thomassen L, Waje-Andreassen U, Naess H
Published Date: 21 January 2014
Published Date: 12 July 2012
AP Coveney, GC O'Brien, GJ Fulton
Published Date: 7 January 2011
Efficacy, safety and tolerability of combination therapy with timolol and dorzolamide in glaucoma and ocular hypertension
Parul Ichhpujani, L Jay Katz
Published Date: 24 May 2010
Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies
Darren D O’Rielly, Proton Rahman
Published Date: 30 March 2010